Long Island University

About: Long Island University is a education organization based out in Brookville, New York, United States. It is known for research contribution in the topics: Population & Context (language use). The organization has 2647 authors who have published 4924 publications receiving 108757 citations.

Novel therapies for treatment of multi-drug resistant Acinetobacter baumannii skin infections

Abstract: The Gram-negative coccobacillus Acinetobacter baumannii (Ab) has become an increasingly prevalent cause of hospital-acquired infections during the last two decades primarily resulting in pneumonia and complicated infections, including wound infections in troops injured in Afghanistan and Iraq. Moreover, the majority of clinical Ab isolates display high-level resistance to commonly utilized antimicrobial drugs, which severely compromises our capacity to care for patients with Ab disease. Thus, radically new approaches are urgently needed. This review focuses on novel therapies that can challenge the evolving ability of Ab to develop resistance and cause disease.

Development and oral bioavailability assessment of a supersaturated self-microemulsifying drug delivery system (SMEDDS) of albendazole.

Abstract: Objectives Albendazole's (ABZ) poor aqueous solubility is a major determinant of its variable therapeutic response (20–50%). The purpose of this study was to develop and optimize the composition of a self-microemulsifying drug delivery system (SMEDDS) of ABZ and assess its oral pharmacokinetics in rabbits. Methods A D-optimal mixture design of experiments was used to select the levels of constraints of the formulation variables. The predicted composition was optimized using four responses: dispersion performance, droplet sizes, dissolution efficiency (DE) and time for 85% drug release (t85%). Key findings The optimal composition of the ABZ-SMEDDS formulation, with approximately 5 mg/g drug loading of ABZ, was predicted to be Cremophor EL (30% w/w), Tween 80 (15% w/w), Capmul PG-8 (10% w/w) and acidified PEG 400 (45% w/w). An increase of 63% in the relative bioavailability compared with the commercial suspension was obtained with ABZ-SMEDDS as measured by albendazole sulfoxide (ABZSO) plasma levels. The area under the curve (AUC024h) and the peak plasma concentration (Cmax) of ABZ-SMEDDS was higher than those obtained with the commercial suspension by 56% and 52%, respectively. Conclusions This study demonstrates a strategy for the development of a supersaturated SMEDDS formulation of a drug with low aqueous solubility.